Newborn screening for congenital adrenal hyperplasia: Utility of liquid chromatography with tandem mass spectrometry as a secondary test.

Toshihiro Tajima
Author Information
  1. Toshihiro Tajima: Department of Pediatrics, Jichi Children's Hospital Medical Center Tochigi, Shimotsuke, Japan.

Abstract

In Japan, newborn screening (NBS) for congenital adrenal hyperplasia (CAH) began in 1989. NBS is useful for early diagnosis and preventing gender misidentification, however, it has a higher false positive rate for CAH compared to other diseases detected by neonatal screening. Recently, it has become clear that using liquid chromatography with tandem mass spectrometry (LC-MS/MS) for second-tier testing reduces false positive rates and repeat blood sampling. LC-MS/MS commonly measures cortisol (F), androstenedione (A4), 11-deoxycortsiol (11DOF), 21-deoxycortisol (21DOF), and 17-hydroxyprogesterone (17OHP) levels. The ratios for (21DOF+17OHP)/F and (17OHP+A4)/F have been used to establish cut-off values for the second-tier test. In Japan, the recall rate is reduced using the 11DOF/17OHP ratio as well as the ratios for (21DOF+17OHP)/F and (17OHP+A4)/F for the second-tier test. Currently, second-tier testing using LC-MS/MS for CAH neonatal screening is unfeasible in all regions of Japan due to equipment costs, however, it will hopefully be available nationwide in the future.

Keywords

References

  1. Int J Neonatal Screen. 2020 Aug 12;6(3):63 [PMID: 33117905]
  2. J Perinat Med. 2014 Jan;42(1):121-7 [PMID: 23989111]
  3. J Clin Endocrinol Metab. 2021 Oct 21;106(11):e4487-e4496 [PMID: 34171085]
  4. BMC Pediatr. 2015 Dec 15;15:209 [PMID: 26671474]
  5. J Clin Endocrinol Metab. 2007 Jul;92(7):2581-9 [PMID: 17456574]
  6. Clin Endocrinol (Oxf). 2021 Feb;94(2):229-236 [PMID: 33001476]
  7. J Clin Endocrinol Metab. 2022 Nov 25;107(12):3341-3352 [PMID: 36071550]
  8. Clin Chim Acta. 2011 Nov 20;412(23-24):2076-84 [PMID: 21803033]
  9. J Inherit Metab Dis. 2007 Aug;30(4):585-92 [PMID: 17643193]
  10. Int J Neonatal Screen. 2019 Sep 06;5(3):33 [PMID: 33072992]
  11. Int J Neonatal Screen. 2020 Aug 28;6(3): [PMID: 33239597]
  12. Pediatr Res. 2009 Aug;66(2):230-5 [PMID: 19390483]
  13. Horm Res Paediatr. 2022;95(1):35-42 [PMID: 35114680]
  14. Horm Res Paediatr. 2022;95(3):255-263 [PMID: 35350013]
  15. Steroids. 2022 Sep;185:109056 [PMID: 35660382]
  16. Clin Pediatr Endocrinol. 2022;31(3):116-143 [PMID: 35928387]
  17. J Clin Endocrinol Metab. 2018 Nov 1;103(11):4043-4088 [PMID: 30272171]
  18. Clin Chem. 2004 Mar;50(3):621-5 [PMID: 14656905]
  19. Clin Endocrinol (Oxf). 2021 Jun;94(6):904-912 [PMID: 33471388]
  20. Clin Pediatr Endocrinol. 2016 Jan;25(1):1-8 [PMID: 26865749]
  21. Int J Neonatal Screen. 2022 Oct 21;8(4): [PMID: 36278626]
  22. Pediatr Endocrinol Rev. 2012 Oct;10 Suppl 1:72-8 [PMID: 23330248]

Word Cloud

Created with Highcharts 10.0.0screeningsecond-tier/FJapancongenitaladrenalCAHfalsepositiverateusingliquidchromatographytandemmassspectrometryLC-MS/MStestNBShyperplasiahoweverneonataltestingratios21DOF+17OHP17OHP+A4recallnewbornbegan1989usefulearlydiagnosispreventinggendermisidentificationhighercompareddiseasesdetectedRecentlybecomeclearreducesratesrepeatbloodsamplingcommonlymeasurescortisolFandrostenedioneA411-deoxycortsiol11DOF21-deoxycortisol21DOF17-hydroxyprogesterone17OHPlevelsusedestablishcut-offvaluesreduced11DOF/17OHPratiowellCurrentlyunfeasibleregionsdueequipmentcostswillhopefullyavailablenationwidefutureNewbornhyperplasia:Utilitysecondary11-deoxycortisol

Similar Articles

Cited By

No available data.